Изучение антимикробной активности координационных соединений иода в отношении бактерий с множественной лекарственной устойчивостью
DOI:
https://doi.org/10.26577/eb-2018-1-1322Аннотация
Несмотря на увеличение количества новых антибактериальных препаратов на фармацевтическом рынке, возникновение антибиотикорезистентности в настоящее время является глобальной медицинской и социальной проблемой. В связи с этим разработка и создание принципиально новых антимикробных препаратов неантибиотического ряда для лечения инфекционных заболеваний, вызванных множественно устойчивыми микроорганизмами является актуальной проблемой.
Вещества галогенового ряда характеризуются сильным бактерицидным действием на грамположительные и грамотрицательные бактерии, а также повышают липофильность лекарственных веществ и облегчает их прохождение через биомембраны. Создание комплексов органических соединений (производных углеводов, аминокислот) с галогенами, приводит к появлению новых видов биоактивностей или заметному усилению имеющихся.
Целью данного исследования являлось изучение антимикробной активности оригинальных координационных соединений в отношении микроорганизмов со множественной лекарственной устойчивостью и их скрининг на определение наиболее эффективных антимикробных агентов с целью дальнейшего исследования. Оригинальные соединения, упоминаемые в исследовании, получены путем реакции комплексообразования между ионами лития/калия, иода и органических лигандов. В качестве тест-штаммов использовались мультирезистентные и чувствительные микроорганизмы Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa. Определение минимальной бактерицидной концентрации осуществлялось методом двукратных серийных разведений в жидкой среде.
В ходе исследования, несмотря на несомненно высокую антибактериальную активность всех 8 исследуемых образцов, было выделено 3 координационных соединения, обладающих наибольшим антимикробным эффектом в отношении мультирезистентных штаммов. Полученные результаты обуславливают перспективность дальнейшего изучения данных соединений с целью создания в будущем таких антимикробных препаратов, которые не вызывали бы возникновения резистентности микроорганизмов, а также могли бы использоваться в отношении уже существующих мультирезистентых штаммов.
Ключевые слова: координационные соединения иода, антимикробная активность, мультирезистентные микроорганизмы.
Библиографические ссылки
1 Akortha E.E., Ibadin O.K. Incidence and antibiotic susceptibility pattern of Staphylococcus aureus amongst patients with urinary tract infection (UTIS) in UBTH Benin City, Nigeria // African Journal of Biotechnology. – 2008. - Vol. 10, No 11. - P. 1637–1640. doi: 10.5897/AJB08.176.
2 Aminzadeh Z., Sadat Kashi M., Shabani M. Bacteriuria by extended-spectrum Beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: isolates in a governmental hospital in South of Tehran, Iran // Iranian Journal of Kidney Diseases. – 2008. - Vol. 2, No 4. - P. 197–200. PMID: 19377237.
3 Bashar H. The antibiotics market // Nat Rev Drug Discov. – 2010. - Vol. 9, No 9. - P. 675–676. doi: 10.1038/nrd3267.
4 Bloomfield S.F. Chlorine and iodine formulations // Handbook of disinfectants and antiseptics. – P. 133–158.
5 Cantón R., Bryan J. Global antimicrobial resistance: from surveillance to stewardship. Part 1: surveillance and risk factors for resistance // Expert Review of Anti-Infective Therapy. – 2012. - Vol. 10, No 11. - P. 1269–1271. doi: 10.1586/eri.12.120.
6 Cholley P., Thouverez M., Hocquet D., van der Mee-Marquet N., Talon D., Bertrand X. Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types // J Clin Microbiol. – 2011. - Vol. 49, No 7. - P. 2578–2583. doi: 10.1128/JCM.00102-11.
7 Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing, 26th ed. CLSI supplement M100S (ISBN 1-56238-923-8 [Print]; ISBN 1-56238- 924-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2016.
8 Feldman C., Anderson R. Antibiotic resistance of pathogens causing community-acquired pneumonia // Semin Respir Crit Care Med. – 2012. - Vol. 33, No 3. - P. 232–243. doi: 10.1055/s-0032-1315635.
9 Gaynes R., Edwards J.R. Overview of nosocomial infections caused by Gram-negative bacilli // Clin. Infect. Dis. – 2005. - Vol. 41, No 6. – P. 848–854. doi: 10.1086/432803.
10 Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. - Virtual press conference. - 2017. - (http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/).
11 Gouriprasanna R., Munirathinam N., Mugesh G. Interaction of anti-thyroid drugs with iodine: the isolation of two unusual ionic compounds derived from Semethimazole // Org. Biomol. Chem. – 2006. - Vol. 4, No 15. - P. 2883–2887. doi: 10.1039/b604060h.
12 Gutierrez J., Hossam A., Lazarezcu R., et al. Effect of beta blockers on sepsis outcome // Med Sci Monit. – 2009. - Vol. 15, No 10. - P. 499–503. PMID: 19789508.
13 Hirsch E.B., Vincent H.T. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes // Expert Rev Pharmacoecon Outcomes Res. – 2010. - Vol. 10, No 4. - P. 441–451. doi: 10.1586/erp.10.49.
14 Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis // N Engl J Med. – 2003. - Vol. 348, No 2. - P. 138–150. doi: 10.1056/NEJMra021333.
15 Iwamoto M., Mu Y., Lynfield R., Bulens S.N., Nadle J., Aragon D., Petit S., Ray S.M., Harrison L.H., Dumyati G., Townes J.M., Schaffner W., Gorwitz R.J., Lessa F.C. Trends in invasive methicillin-resistant Staphylococcus aureus infections // Pediatrics. – 2013. - Vol. 132, No 4. - P. 817–824. doi: 10.1542/peds.2013-1112.
16 Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., Harrison L.H., Lynfield R., Dumyati G., Townes J.M., Craig A.S., Zell E.R., Fosheim G.E., McDougal L.K., Carey R.B., Fridkin S.K. Active bacterial core surveillance (ABCs) MRSA investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States // Journal of the American Medical Association. – 2007. - Vol. 298, No 15. - P. 1763–1771. doi: 10.1001/jama.298.15.1763.
17 Ludwig E., Bonanni P., Rohde G., Sayiner A., Torres A. The remaining challenges of pneumococcal disease in adults // Eur Respir Rev. – 2012. - Vol. 21, No 123. - P. 57–65. doi: 10.1183/09059180.00008911.
18 Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., Harbarth S., Hindler J.F., Kahlmeter G., Olsson-Liljequist B., Paterson D.L., Rice L.B., Stelling J., Struelens M.J., Vatopoulos A., Weber J.T., Monnet D.L. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance // Clin Microbiol Infect. – 2012. - Vol. 18, No 3. - P. 268–281. doi: 10.1111/j.1469-0691.2011.03570.x.
19 Master R.N., Clark R.B., Karlowsky J.A., Ramirez J., Bordon J.M. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009 // Int J Antimicrob Agents. – 2011. - Vol. 38, No 4. – P. 291–295. doi: 10.1016/j.ijantimicag.2011.04.022.
20 Mehndiratta P.L., Gur R., Saini S., et al. Staphylococcus aureus phage types and their correlation to antibiotic resistance // Indian Journal of Pathology and Microbiology. – 2010. - Vol. 53, No 4. - P. 738–741. doi: 10.4103/0377-4929.72065.
21 Mehrgan H., Rahbar M. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran // International Journal of Antimicrobial Agents. – 2008. - Vol. 31, No 2. - P. 147–151. doi: 10.1016/j.ijantimicag.2007.09.008.
22 Monnet D.L. Antibiotic development and the changing role of the pharmaceutical industry / Monnet D.L. // The global threat of antibiotic resistance. A multidisciplinary meeting at the Dag Hammarskjo Foundation. Uppsala, Sweden. - 2004.
(https://www.dhf.uu.se/antibiotics_participant/new_pdf/Industry.pdf).
23 Monnet D.L. Antibiotic development and the changing role of the pharmaceutical industry // International Journal of Risk & Safety in Medicine. – 2005. - Vol. 17. - P. 133–145.
24 Paterson D.L. Extended-spectrum beta-lactamases: a clinical update // Clinical Microbiology Reviews. – 2005. - Vol.18, No 4. - P. 657–686. doi: 10.1128/CMR.18.4.657-686.2005.
25 Power E. Impact of antibiotic restrictions: the pharmaceutical perspective // Clinical Microbiology and Infection. – 2006. - Vol. 12. - P. 25–34. doi: 10.1111/j.1469-0691.2006.01528.x.
26 Singh V. Antimicrobial resistance // Microbial Pathogens and Strategies for Combating Them: Science, Technology and Education. – 2013. - P. 291–296.
27 Taylor G.R., Butler M.A. Comparison of the virucidal properties of chlorine, chlorine dioxide, bromine chloride and iodine // The Journal of Hygiene. – 1982. - Vol. 89, No 2. – P. 321–328. PMID: 6290566.
28 Гостев В.В., Сидоренко С.В. Метициллинрезистентные золотистые стафилококки: проблема распространения в мире и россии // Фарматека. – 2015. - № 6. – С.30-38.
29 Бекешева К.Б., Курманалиева А.Р., Баринов Д.В., Устенова Г.О. Современное состояние и перспективы применения иодсодержащих препаратов // Медицина. – 2015. - №12 (162). – C. 123-125.
30 Калыкова А.С. Разработка новых лекарственных средств на основе субстанции ФС-1 и их стандартизация : дис. док. PhD : 6D074800 : защищена 30.11.15 / Калыкова Асем Сериковна. – А., 2015. – 164 с. – Библиогр.: с. 12–18. – 615.31.012.07.
References
1. Akortha E.E., Ibadin O.K. (2008) Incidence and antibiotic susceptibility pattern of Staphylococcus aureus amongst patients with urinary tract infection (UTIS) in UBTH Benin City, Nigeria. African Journal of Biotechnology, vol. 10, no 11, pp. 1637–1640, doi: 10.5897/AJB08.176.
2. Aminzadeh Z., Sadat Kashi M., Shabani M. (2008) Bacteriuria by extended-spectrum Beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: isolates in a governmental hospital in South of Tehran, Iran. Iranian Journal of Kidney Diseases, vol. 2, no 4, pp. 197–200, PMID: 19377237
3. Bashar H. (2010) The antibiotics market. Nat Rev Drug Discov., vol. 9, no 9, pp. 675-676, doi: 10.1038/nrd3267.
4. Bekesheva K., Kurmanaliyeva A., Barinov D., Ustegenova G. (2015) Sovremennoe sostoyanie i perspectivy primeneniya iodsoderzhaschih preparatov [The contemporary state and prospects of of iodine-containing drugs treatment]. Medicina (Medicine), no. 12, pp. 123-125, doi: 615.777.12/.453.6:004.14.
5. Bloomfield S.F. (1996) Chlorine and iodine formulations, In: Ascenzi J M, editor. Handbook of disinfectants and antiseptics. (New York, N.Y: Marcel Dekker, Inc., 1996), pp. 133–158.
6. Cantón R., Bryan J. (2012) Global antimicrobial resistance: from surveillance to stewardship. Part 1: surveillance and risk factors for resistance. Expert Review of Anti-Infective Therapy, vol. 10, no 11, pp. 1269–1271, doi: 10.1586/eri.12.120.
7. Cholley P., Thouverez M., Hocquet D., van der Mee-Marquet N., Talon D., Bertrand X. (2011) Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types. J Clin Microbiol, vol. 49, no 7, pp. 2578–2583, doi: 10.1128/JCM.00102-11.
8. Clinical and Laboratory Standards Institute (CLSI) (2016) Performance Standards for Antimicrobial Susceptibility Testing, 26th ed. CLSI supplement M100S (ISBN 1-56238-923-8 [Print]; ISBN 1-56238- 924-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA.
9. Feldman C., Anderson R. (2012) Antibiotic resistance of pathogens causing community-acquired pneumonia. Semin Respir Crit Care Med., vol. 33, no 3, pp. 232–243, doi: 10.1055/s-0032-1315635.
10. Gaynes R., Edwards J.R. (2005) Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect. Dis., vol. 41, no 6, pp. 848-854, doi: 10.1086/432803.
11. “Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics,” Virtual press conference, 27 February 2017, http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/.
12. Gostev V., Sidorenko S. (2015) Meticillinrezistentnye zolotistye staphylococci: problema rasprostraneniya v mire i Rossii [Methicillin-resistant Staphylococcus aureus: the problem of expansion in the world and in Russia]. Pharmateka (Pharmateca), no 6, pp. 30-38.
13. Gouriprasanna R., Munirathinam N., Mugesh G. (2006) Interaction of anti-thyroid drugs with iodine: the isolation of two unusual ionic compounds derived from Semethimazole. Org. Biomol. Chem., vol. 4, no 15, pp. 2883-2887, doi: 10.1039/b604060h.
14. Gutierrez J., Hossam A., Lazarezcu R., et al. (2009) Effect of beta blockers on sepsis outcome. Med Sci Monit., vol. 15, no 10, pp. 499–503, PMID: 19789508.
15. Hirsch E.B., Vincent H.T. (2010) Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res., vol. 10, no 4, pp. 441-451, doi: 10.1586/erp.10.49.
16. Hotchkiss R.S., Karl I.E. (2003) The pathophysiology and treatment of sepsis. N Engl J Med., vol. 348, no 2, pp. 138–150, doi: 10.1056/NEJMra021333.
17. Iwamoto M., Mu Y., Lynfield R., Bulens S.N., Nadle J., Aragon D., Petit S., Ray S.M., Harrison L.H., Dumyati G., Townes J.M., Schaffner W., Gorwitz R.J., Lessa F.C. (2013) Trends in invasive methicillin-resistant Staphylococcus aureus infections. Pediatrics, vol. 132, no 4, pp. 817–824, doi: 10.1542/peds.2013-1112.
18. Kalykova A.S. Development of new pharmaceuticals on the basis of FS-1 substance and their standardization (PhD diss., Kazakh National Medical University, 2015), рр.12-18.
19. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., Harrison L.H., Lynfield R., Dumyati G., Townes J.M., Craig A.S., Zell E.R., Fosheim G.E., McDougal L.K., Carey R.B., Fridkin S.K. (2007) Active bacterial core surveillance (ABCs) MRSA investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. Journal of the American Medical Association, vol. 298, no 15, pp. 1763–1771, doi: 10.1001/jama.298.15.1763.
20. Ludwig E., Bonanni P., Rohde G., Sayiner A., Torres A. (2012) The remaining challenges of pneumococcal disease in adults. Eur Respir Rev., vol. 21, no 123, pp. 57-65, doi: 10.1183/09059180.00008911.
21. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., Harbarth S., Hindler J.F., Kahlmeter G., Olsson-Liljequist B., Paterson D.L., Rice L.B., Stelling J., Struelens M.J., Vatopoulos A., Weber J.T, Monnet D.L. (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect., vol. 18, no 3, pp. 268–281, doi: 10.1111/j.1469-0691.2011.03570.x.
22. Master R.N., Clark R.B., Karlowsky J.A., Ramirez J., Bordon J.M. (2011) Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009. Int J Antimicrob Agents., vol. 38, no 4, pp. 291-295, doi: 10.1016/j.ijantimicag.2011.04.022.
23. Mehndiratta P.L., Gur R., Saini S., et al. (2010) Staphylococcus aureus phage types and their correlation to antibiotic resistance. Indian Journal of Pathology and Microbiology, vol. 53, no 4, pp. 738–741, doi: 10.4103/0377-4929.72065.
24. Mehrgan H., Rahbar M. (2008) Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran. International Journal of Antimicrobial Agents, vol. 31, no 2, pp. 147–151, doi: 10.1016/j.ijantimicag.2007.09.008.
25. Monnet D.L. (2004) Antibiotic development and the changing role of the pharmaceutical industry. The global threat of antibiotic resistance. A multidisciplinary meeting at the Dag Hammarskjo Foundation. Uppsala, Sweden, https://www.dhf.uu.se/antibiotics_participant/new_pdf/Industry.pdf.
26. Monnet D.L. (2005) Antibiotic development and the changing role of the pharmaceutical industry. International Journal of Risk & Safety in Medicine, vol. 17, pp. 133–145.
27. Paterson D.L. (2005) Extended-spectrum beta-lactamases: a clinical update. Clinical Microbiology Reviews, vol.18, no 4, pp. 657–686, doi: 10.1128/CMR.18.4.657-686.2005.
28. Power E. (2006) Impact of antibiotic restrictions: the pharmaceutical perspective. Clinical Microbiology and Infection, vol. 12, pp. 25-34, doi: 10.1111/j.1469-0691.2006.01528.x.
29. Singh V. (2013) Antimicrobial resistance. Microbial Pathogens and Strategies for Combating Them: Science, Technology and Education, pp. 291–296.
30. Taylor G.R., Butler M. (1982) A comparison of the virucidal properties of chlorine, chlorine dioxide, bromine chloride and iodine. The Journal of Hygiene, vol. 89, no 2, pp. 321–328, PMID: 6290566.
2 Aminzadeh Z., Sadat Kashi M., Shabani M. Bacteriuria by extended-spectrum Beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: isolates in a governmental hospital in South of Tehran, Iran // Iranian Journal of Kidney Diseases. – 2008. - Vol. 2, No 4. - P. 197–200. PMID: 19377237.
3 Bashar H. The antibiotics market // Nat Rev Drug Discov. – 2010. - Vol. 9, No 9. - P. 675–676. doi: 10.1038/nrd3267.
4 Bloomfield S.F. Chlorine and iodine formulations // Handbook of disinfectants and antiseptics. – P. 133–158.
5 Cantón R., Bryan J. Global antimicrobial resistance: from surveillance to stewardship. Part 1: surveillance and risk factors for resistance // Expert Review of Anti-Infective Therapy. – 2012. - Vol. 10, No 11. - P. 1269–1271. doi: 10.1586/eri.12.120.
6 Cholley P., Thouverez M., Hocquet D., van der Mee-Marquet N., Talon D., Bertrand X. Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types // J Clin Microbiol. – 2011. - Vol. 49, No 7. - P. 2578–2583. doi: 10.1128/JCM.00102-11.
7 Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing, 26th ed. CLSI supplement M100S (ISBN 1-56238-923-8 [Print]; ISBN 1-56238- 924-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2016.
8 Feldman C., Anderson R. Antibiotic resistance of pathogens causing community-acquired pneumonia // Semin Respir Crit Care Med. – 2012. - Vol. 33, No 3. - P. 232–243. doi: 10.1055/s-0032-1315635.
9 Gaynes R., Edwards J.R. Overview of nosocomial infections caused by Gram-negative bacilli // Clin. Infect. Dis. – 2005. - Vol. 41, No 6. – P. 848–854. doi: 10.1086/432803.
10 Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. - Virtual press conference. - 2017. - (http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/).
11 Gouriprasanna R., Munirathinam N., Mugesh G. Interaction of anti-thyroid drugs with iodine: the isolation of two unusual ionic compounds derived from Semethimazole // Org. Biomol. Chem. – 2006. - Vol. 4, No 15. - P. 2883–2887. doi: 10.1039/b604060h.
12 Gutierrez J., Hossam A., Lazarezcu R., et al. Effect of beta blockers on sepsis outcome // Med Sci Monit. – 2009. - Vol. 15, No 10. - P. 499–503. PMID: 19789508.
13 Hirsch E.B., Vincent H.T. Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes // Expert Rev Pharmacoecon Outcomes Res. – 2010. - Vol. 10, No 4. - P. 441–451. doi: 10.1586/erp.10.49.
14 Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis // N Engl J Med. – 2003. - Vol. 348, No 2. - P. 138–150. doi: 10.1056/NEJMra021333.
15 Iwamoto M., Mu Y., Lynfield R., Bulens S.N., Nadle J., Aragon D., Petit S., Ray S.M., Harrison L.H., Dumyati G., Townes J.M., Schaffner W., Gorwitz R.J., Lessa F.C. Trends in invasive methicillin-resistant Staphylococcus aureus infections // Pediatrics. – 2013. - Vol. 132, No 4. - P. 817–824. doi: 10.1542/peds.2013-1112.
16 Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., Harrison L.H., Lynfield R., Dumyati G., Townes J.M., Craig A.S., Zell E.R., Fosheim G.E., McDougal L.K., Carey R.B., Fridkin S.K. Active bacterial core surveillance (ABCs) MRSA investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States // Journal of the American Medical Association. – 2007. - Vol. 298, No 15. - P. 1763–1771. doi: 10.1001/jama.298.15.1763.
17 Ludwig E., Bonanni P., Rohde G., Sayiner A., Torres A. The remaining challenges of pneumococcal disease in adults // Eur Respir Rev. – 2012. - Vol. 21, No 123. - P. 57–65. doi: 10.1183/09059180.00008911.
18 Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., Harbarth S., Hindler J.F., Kahlmeter G., Olsson-Liljequist B., Paterson D.L., Rice L.B., Stelling J., Struelens M.J., Vatopoulos A., Weber J.T., Monnet D.L. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance // Clin Microbiol Infect. – 2012. - Vol. 18, No 3. - P. 268–281. doi: 10.1111/j.1469-0691.2011.03570.x.
19 Master R.N., Clark R.B., Karlowsky J.A., Ramirez J., Bordon J.M. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009 // Int J Antimicrob Agents. – 2011. - Vol. 38, No 4. – P. 291–295. doi: 10.1016/j.ijantimicag.2011.04.022.
20 Mehndiratta P.L., Gur R., Saini S., et al. Staphylococcus aureus phage types and their correlation to antibiotic resistance // Indian Journal of Pathology and Microbiology. – 2010. - Vol. 53, No 4. - P. 738–741. doi: 10.4103/0377-4929.72065.
21 Mehrgan H., Rahbar M. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran // International Journal of Antimicrobial Agents. – 2008. - Vol. 31, No 2. - P. 147–151. doi: 10.1016/j.ijantimicag.2007.09.008.
22 Monnet D.L. Antibiotic development and the changing role of the pharmaceutical industry / Monnet D.L. // The global threat of antibiotic resistance. A multidisciplinary meeting at the Dag Hammarskjo Foundation. Uppsala, Sweden. - 2004.
(https://www.dhf.uu.se/antibiotics_participant/new_pdf/Industry.pdf).
23 Monnet D.L. Antibiotic development and the changing role of the pharmaceutical industry // International Journal of Risk & Safety in Medicine. – 2005. - Vol. 17. - P. 133–145.
24 Paterson D.L. Extended-spectrum beta-lactamases: a clinical update // Clinical Microbiology Reviews. – 2005. - Vol.18, No 4. - P. 657–686. doi: 10.1128/CMR.18.4.657-686.2005.
25 Power E. Impact of antibiotic restrictions: the pharmaceutical perspective // Clinical Microbiology and Infection. – 2006. - Vol. 12. - P. 25–34. doi: 10.1111/j.1469-0691.2006.01528.x.
26 Singh V. Antimicrobial resistance // Microbial Pathogens and Strategies for Combating Them: Science, Technology and Education. – 2013. - P. 291–296.
27 Taylor G.R., Butler M.A. Comparison of the virucidal properties of chlorine, chlorine dioxide, bromine chloride and iodine // The Journal of Hygiene. – 1982. - Vol. 89, No 2. – P. 321–328. PMID: 6290566.
28 Гостев В.В., Сидоренко С.В. Метициллинрезистентные золотистые стафилококки: проблема распространения в мире и россии // Фарматека. – 2015. - № 6. – С.30-38.
29 Бекешева К.Б., Курманалиева А.Р., Баринов Д.В., Устенова Г.О. Современное состояние и перспективы применения иодсодержащих препаратов // Медицина. – 2015. - №12 (162). – C. 123-125.
30 Калыкова А.С. Разработка новых лекарственных средств на основе субстанции ФС-1 и их стандартизация : дис. док. PhD : 6D074800 : защищена 30.11.15 / Калыкова Асем Сериковна. – А., 2015. – 164 с. – Библиогр.: с. 12–18. – 615.31.012.07.
References
1. Akortha E.E., Ibadin O.K. (2008) Incidence and antibiotic susceptibility pattern of Staphylococcus aureus amongst patients with urinary tract infection (UTIS) in UBTH Benin City, Nigeria. African Journal of Biotechnology, vol. 10, no 11, pp. 1637–1640, doi: 10.5897/AJB08.176.
2. Aminzadeh Z., Sadat Kashi M., Shabani M. (2008) Bacteriuria by extended-spectrum Beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: isolates in a governmental hospital in South of Tehran, Iran. Iranian Journal of Kidney Diseases, vol. 2, no 4, pp. 197–200, PMID: 19377237
3. Bashar H. (2010) The antibiotics market. Nat Rev Drug Discov., vol. 9, no 9, pp. 675-676, doi: 10.1038/nrd3267.
4. Bekesheva K., Kurmanaliyeva A., Barinov D., Ustegenova G. (2015) Sovremennoe sostoyanie i perspectivy primeneniya iodsoderzhaschih preparatov [The contemporary state and prospects of of iodine-containing drugs treatment]. Medicina (Medicine), no. 12, pp. 123-125, doi: 615.777.12/.453.6:004.14.
5. Bloomfield S.F. (1996) Chlorine and iodine formulations, In: Ascenzi J M, editor. Handbook of disinfectants and antiseptics. (New York, N.Y: Marcel Dekker, Inc., 1996), pp. 133–158.
6. Cantón R., Bryan J. (2012) Global antimicrobial resistance: from surveillance to stewardship. Part 1: surveillance and risk factors for resistance. Expert Review of Anti-Infective Therapy, vol. 10, no 11, pp. 1269–1271, doi: 10.1586/eri.12.120.
7. Cholley P., Thouverez M., Hocquet D., van der Mee-Marquet N., Talon D., Bertrand X. (2011) Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types. J Clin Microbiol, vol. 49, no 7, pp. 2578–2583, doi: 10.1128/JCM.00102-11.
8. Clinical and Laboratory Standards Institute (CLSI) (2016) Performance Standards for Antimicrobial Susceptibility Testing, 26th ed. CLSI supplement M100S (ISBN 1-56238-923-8 [Print]; ISBN 1-56238- 924-6 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA.
9. Feldman C., Anderson R. (2012) Antibiotic resistance of pathogens causing community-acquired pneumonia. Semin Respir Crit Care Med., vol. 33, no 3, pp. 232–243, doi: 10.1055/s-0032-1315635.
10. Gaynes R., Edwards J.R. (2005) Overview of nosocomial infections caused by Gram-negative bacilli. Clin. Infect. Dis., vol. 41, no 6, pp. 848-854, doi: 10.1086/432803.
11. “Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics,” Virtual press conference, 27 February 2017, http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/.
12. Gostev V., Sidorenko S. (2015) Meticillinrezistentnye zolotistye staphylococci: problema rasprostraneniya v mire i Rossii [Methicillin-resistant Staphylococcus aureus: the problem of expansion in the world and in Russia]. Pharmateka (Pharmateca), no 6, pp. 30-38.
13. Gouriprasanna R., Munirathinam N., Mugesh G. (2006) Interaction of anti-thyroid drugs with iodine: the isolation of two unusual ionic compounds derived from Semethimazole. Org. Biomol. Chem., vol. 4, no 15, pp. 2883-2887, doi: 10.1039/b604060h.
14. Gutierrez J., Hossam A., Lazarezcu R., et al. (2009) Effect of beta blockers on sepsis outcome. Med Sci Monit., vol. 15, no 10, pp. 499–503, PMID: 19789508.
15. Hirsch E.B., Vincent H.T. (2010) Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes. Expert Rev Pharmacoecon Outcomes Res., vol. 10, no 4, pp. 441-451, doi: 10.1586/erp.10.49.
16. Hotchkiss R.S., Karl I.E. (2003) The pathophysiology and treatment of sepsis. N Engl J Med., vol. 348, no 2, pp. 138–150, doi: 10.1056/NEJMra021333.
17. Iwamoto M., Mu Y., Lynfield R., Bulens S.N., Nadle J., Aragon D., Petit S., Ray S.M., Harrison L.H., Dumyati G., Townes J.M., Schaffner W., Gorwitz R.J., Lessa F.C. (2013) Trends in invasive methicillin-resistant Staphylococcus aureus infections. Pediatrics, vol. 132, no 4, pp. 817–824, doi: 10.1542/peds.2013-1112.
18. Kalykova A.S. Development of new pharmaceuticals on the basis of FS-1 substance and their standardization (PhD diss., Kazakh National Medical University, 2015), рр.12-18.
19. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., Harrison L.H., Lynfield R., Dumyati G., Townes J.M., Craig A.S., Zell E.R., Fosheim G.E., McDougal L.K., Carey R.B., Fridkin S.K. (2007) Active bacterial core surveillance (ABCs) MRSA investigators. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. Journal of the American Medical Association, vol. 298, no 15, pp. 1763–1771, doi: 10.1001/jama.298.15.1763.
20. Ludwig E., Bonanni P., Rohde G., Sayiner A., Torres A. (2012) The remaining challenges of pneumococcal disease in adults. Eur Respir Rev., vol. 21, no 123, pp. 57-65, doi: 10.1183/09059180.00008911.
21. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.E., Giske C.G., Harbarth S., Hindler J.F., Kahlmeter G., Olsson-Liljequist B., Paterson D.L., Rice L.B., Stelling J., Struelens M.J., Vatopoulos A., Weber J.T, Monnet D.L. (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect., vol. 18, no 3, pp. 268–281, doi: 10.1111/j.1469-0691.2011.03570.x.
22. Master R.N., Clark R.B., Karlowsky J.A., Ramirez J., Bordon J.M. (2011) Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009. Int J Antimicrob Agents., vol. 38, no 4, pp. 291-295, doi: 10.1016/j.ijantimicag.2011.04.022.
23. Mehndiratta P.L., Gur R., Saini S., et al. (2010) Staphylococcus aureus phage types and their correlation to antibiotic resistance. Indian Journal of Pathology and Microbiology, vol. 53, no 4, pp. 738–741, doi: 10.4103/0377-4929.72065.
24. Mehrgan H., Rahbar M. (2008) Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care hospital in Tehran, Iran. International Journal of Antimicrobial Agents, vol. 31, no 2, pp. 147–151, doi: 10.1016/j.ijantimicag.2007.09.008.
25. Monnet D.L. (2004) Antibiotic development and the changing role of the pharmaceutical industry. The global threat of antibiotic resistance. A multidisciplinary meeting at the Dag Hammarskjo Foundation. Uppsala, Sweden, https://www.dhf.uu.se/antibiotics_participant/new_pdf/Industry.pdf.
26. Monnet D.L. (2005) Antibiotic development and the changing role of the pharmaceutical industry. International Journal of Risk & Safety in Medicine, vol. 17, pp. 133–145.
27. Paterson D.L. (2005) Extended-spectrum beta-lactamases: a clinical update. Clinical Microbiology Reviews, vol.18, no 4, pp. 657–686, doi: 10.1128/CMR.18.4.657-686.2005.
28. Power E. (2006) Impact of antibiotic restrictions: the pharmaceutical perspective. Clinical Microbiology and Infection, vol. 12, pp. 25-34, doi: 10.1111/j.1469-0691.2006.01528.x.
29. Singh V. (2013) Antimicrobial resistance. Microbial Pathogens and Strategies for Combating Them: Science, Technology and Education, pp. 291–296.
30. Taylor G.R., Butler M. (1982) A comparison of the virucidal properties of chlorine, chlorine dioxide, bromine chloride and iodine. The Journal of Hygiene, vol. 89, no 2, pp. 321–328, PMID: 6290566.
Загрузки
Как цитировать
Jumagaziyeva, A. B., Кеnesheva S. T., Bakytov, D. B., Berdibay, S. B., Paretskaya N. А., Dathayev, U. M., Кarpenyuk Т. А., Tamazyan, R. A., & Ilin, A. I. (2018). Изучение антимикробной активности координационных соединений иода в отношении бактерий с множественной лекарственной устойчивостью. Вестник КазНУ. Серия биологическая, 74(1), 140–151. https://doi.org/10.26577/eb-2018-1-1322
Выпуск
Раздел
МИКРОБИОЛОГИЯ
